CMPX — Compass Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1738021 ·
Last close
$0.61
Market Cap
$109.26M
52W High
$6.88
52W Low
$0.57
ADV30
2,611,959
Next earnings
2026-11-09
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -28,800,000 -27,171,000 174,498,000 41,469,000 31,928,000
Jun 2026 0 — -26,979,000 -25,154,000 190,173,000 35,453,000 24,124,000
Mar 2026 0 — -20,299,000 -18,317,000 205,170,000 55,168,000 18,697,000
Dec 2025 0 — -17,990,000 -15,716,000 219,588,000 30,643,000 22,797,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-61,578,000
Investing CF
$52,407,000
Financing CF
$4,428,000
CapEx
$-371,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.47
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-501,814,000
Inventory
—
Receivables
—
ST Investments
$121,589,000
EBIT TTM
$-94,068,000
Pretax Income TTM
$-86,358,000
Interest Exp TTM
—
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -72,839,000 -66,489,000 219,588,000 22,797,000 196,791,000 -49,143,000
Dec 2024 850,000 -56,625,000 -49,375,000 140,403,000 15,170,000 125,233,000 -44,855,000
Dec 2023 0 -50,363,000 -42,494,000 156,875,000 8,337,000 148,538,000 -40,618,000
Dec 2022 0 -41,655,000 -39,225,000 199,645,000 18,007,000 181,638,000 -34,125,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-73,446,000
OpCashFlow TTM
—
Assets (Latest)
$190,173,000
Forward EPS
$-0.59

Max Pain — expiry 2026-12-18

max pain strike: $1.00 · spot: $0.61 · call oi: 9,412 · put oi: 513
Expected Move to 2026-12-18: ±$0.10 (16.37%) — implied range $0.51 – $0.71 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MOLN MOLECULAR PARTNERS AG $109.55M $2.86 —
LENZ LENZ Therapeutics, Inc. $109.97M $3.50 —
CRDL Cardiol Therapeutics Inc. $113.53M $0.97 —
ENGN enGene Therapeutics Inc. $115.27M $1.72 —
ZURA Zura Bio Ltd $99.70M $1.03 —

News headlines (Yahoo Finance, 1h cache)

Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
2026-11-09 13:00 · Yahoo
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
2026-11-06 14:00 · Yahoo
Compass Therapeutics to Participate in Upcoming November Investor Events
2026-11-02 14:00 · Yahoo
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-14 20:30 · Yahoo
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns
2026-10-14 02:13 · Yahoo
Compass Therapeutics’ FDA Setback Raises Concerns On Wall Street — H.C. Wainwright Calls Tovecimig Filing Strategy ‘Risky’
2026-09-23 13:44 · Yahoo
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
2026-09-22 23:07 · Yahoo
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug
2026-09-22 18:02 · Yahoo
CMPX Stock Crashes To Over 2-Year Lows — Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing
2026-09-22 14:43 · Yahoo
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
2026-07-17 14:42 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.